BDBM569244 US11427563, Compound 111::US11427563, Compound 15::US11427563, Compound 16a::US11427563, Compound 16b

SMILES Fc1ccc(NS(=O)(=O)c2ccc(cc2)C2C[C@H]2C(=O)Nc2ccc3cncc(Cl)c3c2)nc1

InChI Key InChIKey=BSPKIJMBEIELMN-UHFFFAOYSA-N

Data  26 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 26 hits for monomerid = 569244   

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 0.440nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 0.800nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 0.800nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 1nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 2nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 2nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 2nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 2.90nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 4.80nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 4.80nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 4.80nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 7nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 7nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 12nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 25nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 56nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 56nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 56nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 70nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 74nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 88nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 88nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 88nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 156nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 156nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 156nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent